These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36789997)

  • 21. Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis.
    Itzhaki Ben Zadok O; Vaturi M; Vaxman I; Iakobishvili Z; Rhurman-Shahar N; Kornowski R; Hamdan A
    PLoS One; 2021; 16(8):e0255487. PubMed ID: 34370783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.
    García-Pavía P; García-Pinilla JM; Lozano-Bahamonde A; Yun S; García-Quintana A; Gavira-Gómez JJ; Aibar-Arregui MÁ; Barge-Caballero G; Núñez Villota J; Bernal L; Tarilonte P
    Rev Esp Cardiol (Engl Ed); 2024 Jul; ():. PubMed ID: 39089574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis.
    Castano A; Haq M; Narotsky DL; Goldsmith J; Weinberg RL; Morgenstern R; Pozniakoff T; Ruberg FL; Miller EJ; Berk JL; Dispenzieri A; Grogan M; Johnson G; Bokhari S; Maurer MS
    JAMA Cardiol; 2016 Nov; 1(8):880-889. PubMed ID: 27557400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction.
    Goland S; Volodarsky I; Fabricant Y; Livschitz S; Tshori S; Cuciuc V; Zilberman L; Fugenfirov I; Meledin V; Shimoni S; Josfberg S; George J
    PLoS One; 2021; 16(7):e0254104. PubMed ID: 34242301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis.
    Kreusser MM; Volz MJ; Knop B; Ehlermann P; Schmack B; Ruhparwar A; Hegenbart U; Schönland SO; Katus HA; Raake PW
    Clin Res Cardiol; 2020 Jun; 109(6):700-713. PubMed ID: 31630214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction.
    Gehlken C; Screever EM; Suthahar N; van der Meer P; Westenbrink BD; Coster JE; Van Veldhuisen DJ; de Boer RA; Meijers WC
    ESC Heart Fail; 2021 Aug; 8(4):2458-2466. PubMed ID: 34085774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis.
    Bonfioli GB; Tomasoni D; Vergaro G; Castiglione V; Adamo M; Fabiani I; Loghin V; Lombardi CM; Nicolai A; Metra M; Emdin M; Aimo A
    Eur J Heart Fail; 2024 Sep; ():. PubMed ID: 39252401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis.
    Aimo A; Fabiani I; Giannoni A; Mandoli GE; Pastore MC; Vergaro G; Spini V; Chubuchny V; Pasanisi EM; Petersen C; Poggianti E; Taddei C; Castiglione V; Latrofa S; Panichella G; Sciaccaluga C; Georgiopoulos G; Passino C; Cameli M; Emdin M
    Eur Heart J Cardiovasc Imaging; 2022 Dec; 24(1):130-141. PubMed ID: 35292807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extracellular Volume Fraction by Computed Tomography Predicts Long-Term Prognosis Among Patients With Cardiac Amyloidosis.
    Gama F; Rosmini S; Bandula S; Patel KP; Massa P; Tobon-Gomez C; Ecke K; Stroud T; Condron M; Thornton GD; Bennett JB; Wechelakar A; Gillmore JD; Whelan C; Lachmann H; Taylor SA; Pugliese F; Fontana M; Moon JC; Hawkins PN; Treibel TA
    JACC Cardiovasc Imaging; 2022 Dec; 15(12):2082-2094. PubMed ID: 36274040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of the H
    Tada A; Nagai T; Omote K; Iwano H; Tsujinaga S; Kamiya K; Konishi T; Sato T; Komoriyama H; Kobayashi Y; Takenaka S; Mizuguchi Y; Sato T; Yamamoto K; Yoshikawa T; Saito Y; Anzai T
    Int J Cardiol; 2021 Nov; 342():43-48. PubMed ID: 34364907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atrial function and geometry differences in transthyretin versus immunoglobulin light chain amyloidosis: a cardiac magnetic resonance study.
    Palmer C; Truong VT; Slivnick JA; Wolking S; Coleman P; Mazur W; Zareba KM
    Sci Rep; 2022 Jan; 12(1):140. PubMed ID: 34996915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis.
    Donnellan E; Wazni O; Kanj M; Elshazly MB; Hussein A; Baranowski B; Hanna M; Patel D; Trulock K; Martyn M; Menon V; Saliba W; Jaber WA
    Europace; 2020 Feb; 22(2):259-264. PubMed ID: 32031230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electronic health record characterization and outcomes of heart failure with preserved ejection fraction.
    Rao VN; Cyr DD; Wruck LM; Sanders G; Hofmann P; Rössig L; Siedentop H; Evers T; Meyer M; Paraschin K; Nkulikiyinka R; Parikh K; Felker GM
    Am Heart J; 2023 Sep; 263():1-14. PubMed ID: 37116604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of clinical characteristics of cardiac amyloidosis as a potential underlying etiology in patients diagnosed with heart failure with preserved ejection fraction.
    Murat S; Cavusoglu Y; Yalvac HE; Sivrikoz IA; Kocagil S
    Kardiol Pol; 2022; 80(6):672-678. PubMed ID: 35390167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
    Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
    Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generalizability of HFA-PEFF and H
    Faxen UL; Venkateshvaran A; Shah SJ; Lam CSP; Svedlund S; Saraste A; Beussink-Nelson L; Lagerstrom Fermer M; Gan LM; Hage C; Lund LH
    J Card Fail; 2021 Jul; 27(7):756-765. PubMed ID: 33647474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Value of the MAGGIC Score, H
    Przewlocka-Kosmala M; Butler J; Donal E; Ponikowski P; Kosmala W
    J Am Soc Echocardiogr; 2022 Sep; 35(9):966-975. PubMed ID: 35605894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.
    Porcari A; Rossi M; Cappelli F; Canepa M; Musumeci B; Cipriani A; Tini G; Barbati G; Varrà GG; Morelli C; Fumagalli C; Zampieri M; Argirò A; Vianello PF; Sessarego E; Russo D; Sinigiani G; De Michieli L; Di Bella G; Autore C; Perfetto F; Rapezzi C; Sinagra G; Merlo M
    Eur J Heart Fail; 2022 Jul; 24(7):1227-1236. PubMed ID: 35509181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.